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Abstract  
Aims/hypothesis  Fenofibrate caused an acute, sustained plasma creatinine increase in 
the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) studies. We assessed 
fenofibrate’s renal effects in a FIELD washout sub-study. 
Methods  Type 2 diabetic patients (n=9795) aged 50 to 75 years were randomly 
assigned to fenofibrate (n=4895) or placebo (n=4900) for 5 years, after 6 weeks 
fenofibrate run-in. Albuminuria (urinary albumin:creatinine ratio measured at baseline, 
year 2 and close-out) and estimated GFR, measured 4 to 6 monthly according to the 
Modification of Diet in Renal Disease study, were pre-specified endpoints. Plasma 
creatinine was re-measured 8 weeks after treatment cessation at close-out (washout 
sub-study, n=661). Analysis was by intention-to-treat.  
Results  During fenofibrate run-in, plasma creatinine increased by 10.0 µmol/l 
(p<0.001), but quickly reversed on placebo assignment. It remained higher on 
fenofibrate than on placebo, but the chronic rise was slower (1.62 µmol/l vs 1.89 
µmol/l annually, p=0.01), with less estimated GFR loss (1.19 vs 2.03 ml min
−1
 1.73 
m
−2
 annually, p<0.001). After washout, estimated GFR had fallen less from baseline 
on fenofibrate (1.9 ml min
−1
 1.73 m
−2
, p=0.065) than on placebo (6.9 ml min
−1
 1.73 
m
−2
, p<0.001), sparing 5.0 ml min
−1
 1.73 m
−2
 (95% CI 2.3-7.7, p<0.001). Greater 
preservation of estimated GFR with fenofibrate was observed with baseline 
hypertriacylglycerolaemia (n=169 vs 491 without) alone, or combined with low HDL-
cholesterol (n=140 vs 520 without) and reductions of ≥ 0.48 mmol/l in triacylglycerol 
over the active run-in period (pre-randomisation) (n=356 vs 303 without). Fenofibrate 
reduced urine albumin concentrations and hence albumin:creatinine ratio by 24% vs 
12% (p<0.001; mean difference 14% [95% CI 9-18]; p<0.001), with 14% less 
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progression and 18% more albuminuria regression (p<0.001) than in participants on 
placebo. End-stage renal event frequency was similar (n=21 vs 26, p=0.48). 
Conclusions/interpretation  Fenofibrate reduced albuminuria and slowed estimated 
GFR loss over 5 years, despite initially and reversibly increasing plasma creatinine. 
Fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients. 
Confirmatory studies are merited. 
Trial registration: ISRCTN64783481 
Funding: The study was funded by grants from Laboratoires Fournier, Dijon, France 
(now part of Abbott Pharmaceuticals) and the National Health and Medical Research 
Council, Australia. 
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Abbreviations: 
ACCORD - Action to Control Cardiovascular Risk in Diabetes 
ACR - Albumin:creatinine ratio 
FIELD - Fenofibrate Intervention and Event Lowering in Diabetes 
MICRO-HOPE - Microalbuminuria, Cardiovascular, and Renal Outcomes - Heart 
Outcomes Prevention Evaluation. 
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 PAI-1 - Plasminogen activating inhibitor-1 
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Introduction 
Two recent large-scale, double-blind, randomised, placebo-controlled clinical trials, 
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to 
Control Cardiovascular Risk in Diabetes (ACCORD), have shown an early, sustained 
rise in serum creatinine with fenofibrate in patients with type 2 diabetes [1, 2]. Given 
the benefits of reduced cardiovascular events in the subgroups with dyslipidaemia 
(hypertriacylglycerolaemia and low HDL-cholesterol) in both studies and despite 
negative primary endpoints overall (FIELD: non-fatal myocardial infarction and 
coronary death; ACCORD: non-fatal myocardial infarction, non-fatal stroke and 
cardiovascular disease death), it is important to determine the clinical significance of 
this plasma creatinine rise. In both trials, fenofibrate was generally safe and well 
tolerated, but with a small increase in rates of pancreatitis and pulmonary embolism in 
FIELD [1, 2]. In FIELD, fewer microvascular amputations and less laser-requiring 
retinopathy occurred in fenofibrate-treated patients (also confirmed in ACCORD-
EYE [3]), potentially further broadening the clinical applications of fenofibrate [4, 5]. 
 
Diabetes is a leading cause of renal dysfunction and end-stage renal disease. One in 
five diabetic patients progresses to end-stage renal disease within 20 years of 
nephropathy onset [6]. Cardiovascular complications start early in renal disease with 
even minor renal deterioration being associated with arterial thickening [7]. Current 
therapies may not arrest renal function decline and there is an urgent need for new 
targets and interventions [8], as renal failure and associated cardiovascular disease 
increase mortality rates [9]. Fenofibrate has been shown to decrease albuminuria in a 
mouse model of type 2 diabetes [10] and in humans [1, 2, 11]. Given potential renal 
benefit, but the possible safety concerns arising from the rise in plasma creatinine, we 
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carried out a detailed analysis of the effects of long-term fenofibrate treatment on pre-
specified renal outcomes during treatment and after drug cessation.  
 
Methods 
Design overview  FIELD was a randomised, double-blind placebo controlled trial with 
the primary outcome of coronary events. Study design and patient characteristics have 
been published elsewhere [1]. This registered study had ethics committee approval in 
accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.   
 
Setting and participants  Sites (n=63) in Australia, New Zealand and Finland 
recruited 9795 type 2 diabetic participants aged 50 to 75 years and with baseline 
plasma total cholesterol between 3.0 and 6.5 mmol/l, plus total cholesterol:HDL-
cholesterol ratio ≥ 4.0 or plasma triacylglycerol ranging from 1.0 to 5.0 mmol/l, and 
without need of lipid-lowering drugs. Exclusion criteria were plasma creatinine >130 
µmol/l, liver or symptomatic gallbladder disease, or a cardiovascular event within 3 
months prior to recruitment. All patients provided written informed consent and then 
completed a 16 week run-in period comprising 4 weeks of diet, 6 weeks of single-
blind placebo and 6 weeks of single-blind fenofibrate. Eligibility was confirmed 
during run-in independently of adherence or biochemical changes. 
 
Randomisation and interventions  Participants with type 2 diabetes (n=9795) were 
assigned to fenofibrate 200 mg or placebo daily for 5 years on average. A telephone 
computer randomisation service using dynamic balancing to stratify patients by 
prognostic variables was used. All investigators, except the authorised study 
statistician, were masked to treatment allocation before and after randomisation. 
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Outcomes and follow-up  Pre-specified renal endpoints were: (1) renal function 
changes; (2) urinary albumin:creatinine ratio (ACR) changes; and (3) end-stage renal 
disease, defined as plasma creatinine > 400 μmol/l, dialysis, transplant or renal 
disease death. Albuminuria at baseline was defined as: (1) microalbuminuria, i.e. 
urinary ACR ≥ 2.5 and ≥ 3.5 mg/mmol (men and women respectively); and (2) 
macroalbuminuria, i.e. urinary ACR > 25 and ≥ 35 mg/mmol (men and women 
respectively). This definition was revised to be sex-specific after the study was 
unmasked. Estimated GFR was by the Modification of Diet in Renal Disease 
(MDRD) study four-variable formula [12] and categorised as estimated GFR ≥ 90 ml 
min
−1
 1.73 m
−2
; 60 to < 90 ml min
−1
 1.73 m
−2
; 30 to < 60 ml min
−1
 1.73 m
−2
; and < 30 
ml min
−1
 1.73 m
−2
. All measurements of albuminuria and creatinine were performed 
in the central laboratories with regular quality assurance through participation in 
national schemes. Plasma creatinine was measured by the Jaffe reaction (alkaline 
picrate-kinetic) on a clinical chemistry analyser (Hitachi 917; Roche Diagnostics, 
Basel, Switzerland), using calibrators supplied by the manufacturer, with interassay 
CVs over 5 years of 1.3% at a concentration of 170 µmol/l and 1.9% at 600 µmol/l. 
Urinary creatinine was also measured on this analyser after dilution. This method 
showed excellent agreement with isotope-dilution mass spectrometry and recovered 
the certified values assigned to the reference material. 
Urine albumin was measured by immunonephelometry on an analyser (Array 360; 
Beckman, Fullerton, CA, USA), with interassay CVs over 5 years of 2.8% at a 
concentration of 10 mg/l and 2.5% at 50 mg/l. 
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Although estimated GFR may underestimate true glomerular filtration rate [13], 
particularly at > 90 ml min
−1
 1.73 m
−2
, our analyses focused on changes over time and 
between treatments, rather than absolute values.  
 
Vascular complications were self-reported at screening. Lipids, HbA1c, renal function, 
hepatic function and first morning urinary ACR were measured with annual 
calibration. Patients were seen at intervals of 4 to 6 months against a background of 
usual care, and information on treatment toleration and complications was obtained. 
Urinary albumin and creatinine were measured pre-randomisation (the mean of two 
first morning samples) and at year 2, year 5 and close-out. 
 
Washout sub-study  In analyses pre-specified 6 months prior to unmasking of the 
study, 661 patients were re-assessed 52±13 days after close-out to further evaluate the 
known fenofibrate-associated changes in plasma creatinine. Given that fenofibrate has 
a 20 h elimination half-life, this time-point minimised any drug withdrawal rebound 
effect. Sub-study patients all gave consent at the main study close-out at participating 
centres after local ethical approval for the additional washout visit had been granted. 
They had similar baseline characteristics to non-participants and balanced 
characteristics by treatment allocation (Electronic supplementary material [ESM] 
Table 1). At washout-period end, fasting plasma was collected. 
 
Statistical analysis  Comparisons of pre-specified baseline variables used t tests or 
Wilcoxon’s rank-sum tests for continuous variables, and 2  tests for categorical 
variables. Comparisons of changes in estimated GFR between groups used t tests 
within each subgroup. Interaction tests used a linear model, with estimated GFR 
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change as the dependent variable and p value for interaction based on the likelihood 
ratio test for interaction between subgroup and treatment variables. Urinary ACR (log 
transformed) and estimated GFR analyses were similar. Predictors of baseline 
estimated GFR, and changes in plasma creatinine, estimated GFR and urinary ACR 
were determined using linear models and stepwise variable selection from a 
predefined list. Only the analyses relating to changes in estimated GFR from baseline 
to the end of the washout period according to baseline characteristics and changes in 
biomarkers during active run-in were post hoc, in that the associations between the 
pre-specified variables and the pre-specified outcomes were not expressly stated in 
the statistical analysis plan. Numbers needed to treat were calculated by transforming 
the absolute risk reduction. Two-sided p values were significant at p<0.05 and were 
unadjusted for multiple comparisons. 
 
Results 
Of 13900 screened patients, 9795 were randomised to fenofibrate (n=4895) or placebo 
(n=4900) (Fig. 1). The groups were well matched including for renal function, blood 
pressure and glycaemia (Table 1). Approximately 20% reported microvascular 
complications. At baseline, 2508 (26%) patients had increased urinary ACR and 5726 
(59%) had estimated GFR of 30 to 89 ml min
−1
 1.73 m
−2
. Few had macroalbuminuria 
(404, 4%) or estimated GFR of 30 to < 60 ml min
−1
 1.73 m
−2
 (518, 5%). Almost 80% 
with estimated GFR < 90 ml min
−1
 1.73 m
−2
 had normal ACR, and 40% with raised 
ACR had estimated GFR ≥ 90 ml min−1 1.73 m−2 (ESM Table 2).  
 
Fenofibrate effects on plasma creatinine and estimated GFR  Mean plasma creatinine 
increased 10.0 µmol/l during the pre-randomisation 6 week fenofibrate run-in period. 
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In those subsequently randomised to placebo, levels at the next visit (4 months) fell 
back to baseline levels, but then increased by 1.7 µmol/l per year (Fig. 2a). In the 
same group, estimated GFR fell proportionately and below 90 ml min
−1
 1.73 m
−2
 at a 
rate of approximately 5% per annum. Baseline risk factors for greater plasma 
creatinine rise and estimated GFR loss during placebo treatment over 5 years included 
elevated urinary ACR, older age, lower HDL-cholesterol and higher HbA1c (p<0.001 
for all). Placebo patients requiring renin–angiotensin system blockers at entry also had 
greater estimated GFR loss than other participants (p=0.004), possibly representing 
indication bias. 
 
In participants allocated fenofibrate, plasma creatinine remained 10 to 12 µmol/l 
higher than placebo (p<0.001) (Fig. 2a), with an apparently greater fall in  
estimated GFR (87.6 to 70.5 vs 87.8 to 79.9 ml min
−1
 1.73 m
−2
) from pre-run-in 
(baseline) to close-out. However, the long-term plasma creatinine rise (4 months 
to close-out) was smaller with fenofibrate than with placebo, both overall (7.9 
µmol/l vs 9.2 µmol/l, p=0.01) (Fig. 2a), and within each subgroup of baseline 
estimated GFR (ESM Fig. 1). This was paralleled by slower estimated GFR loss 
(5.8 vs 9.9 ml min
−1
 1.73 m
−2
, respectively, p<0.001) (Fig. 2b). The mean annual 
rates of plasma creatinine rise and estimated GFR decline were 1.62 µmol/l vs 
1.89 µmol/l and 1.19 vs 2.03 ml min
−1
 1.73 m
−2
 respectively for patients on 
fenofibrate vs those on placebo. 
In the 661 washout sub-study participants, plasma creatinine changes (baseline to 
closeout) were comparable to those in the whole cohort, but levels at 8 weeks after 
withdrawal of study treatment were significantly lower in participants allocated 
fenofibrate than in those on placebo (p<0.001) (Fig. 3a). This reflected a 5-year fall in 
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estimated GFR of 1.9 ml min
−1
 1.73 m
−2
 in the fenofibrate group (from 89.2 to 87.3; 
p=0.07) vs 6.9 ml min
−1
 1.73 m
−2
 in the placebo group (from 87.5 to 80.6; p<0.001), 
such that fenofibrate spared an average of 5.0 ml min
−1
 1.73 m
−2
 (p<0.001) or ~1 ml 
min
−1
 1.73 m
−2
 annually (Fig. 3b).  
 
Significant renal function decline was seen in all washout subgroups receiving 
placebo (Fig. 4). Independently statistically significant estimated GFR preservation 
with fenofibrate occurred in most subgroups. Evidence of greater benefit was present 
in those with baseline hypertriacylglycerolaemia (>2.3 mmol/l) or dyslipidaemia 
compared with those without (p=0.03 for interaction, for both) (Fig. 4). Benefit also 
differed by treatment response according to the extent of plasma triacylglycerol 
lowering with fenofibrate (during active run-in), being observed continuously 
(p=0.002) and categorically (p=0.02 for interaction) (ESM Table 3), but 
independently of all other variables (including other baseline lipids, blood pressure 
and renin–angiotensin system blocker use) (Fig. 4) and on-study commencement of 
statins or renin–angiotensin system blockers (data not shown). 
 
Albuminuria and effects of fenofibrate  In both groups, urinary ACR fell over 5 years 
(Fig. 2c). Determinants of less than average improvement were low urinary ACR or 
high plasma creatinine at baseline, current smoking, longer diabetes duration and 
older age. Other predictors (also associated with decline in estimated GFR) included 
increased plasma homocysteine, HbA1c and renin–angiotensin-system blocker use 
(p<0.05 for all). The fall was greater in participants on fenofibrate (23.7% vs 11.5%; 
mean difference 13.9% [95% CI 9.2-18.3]; p<0.001). A fall in urinary creatinine 
concentration was observed with fenofibrate, but this was exceeded by the decrease in 
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urinary albumin concentration, reducing the ratio. This equated to a 0.2 mg/mmol 
difference in mean ACR at close-out (fenofibrate 1.1 mg/mmol vs placebo 1.3 
mg/mmol), reflecting 11.7, 1.0 and 0.1 mg/mmol differences among macro-, micro- 
and normoalbuminuric participants respectively (ESM Fig. 2). A shift across 
categories occurred, favouring fenofibrate, with 14% less progression (11.1% vs 
12.9%) and 18% more regression (11.2% vs 9.5%; p<0.001) (ESM Table 4). These 
benefits were similar for all subgroups (including renin–angiotensin system blocker 
use), except sex, with larger effects among men than women (post hoc analysis, data 
not shown).  
 
More advanced renal endpoints  Plasma creatinine doubling was more common in 
participants on fenofibrate than in those on placebo (3.0% vs 1.8%, p<0.001), but was 
often transient and seldom led to withdrawal (7 vs 2, p=0.1). End-stage renal disease 
(creatinine > 400 µmol/l [n=6 vs 3], dialysis [n=16 vs 21], renal transplant [n=0 vs 0] 
and/or renal death [n=1 vs 4]) did not differ between groups (21 in fenofibrate group 
vs 26 for placebo, p=0.48) (Table 2). The reduction in the secondary endpoint of total 
cardiovascular events was no smaller in participants with larger creatinine increases 
and on fenofibrate than in others (ESM Fig. 3).  
 
Discussion 
Diabetes, a leading cause of renal damage and end-stage renal disease [6, 14], is 
associated with increased mortality rates and substantial personal and economic cost 
[14]. In 2007 one US diabetic patient started dialysis every 11 min, with associated 
total costs of US$33 billion [14]. An ageing population and increasing diabetes 
prevalence will increase the burden of diabetic renal disease [8]. Despite multi-
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factorial treatment in the STENO-2 trial, renal disease still developed in 25% of 
patients over 13 years [15]. We demonstrate here that fenofibrate reduces albuminuria 
progression and decline of estimated GFR in type 2 diabetes patients, despite a small 
initial plasma creatinine rise. The greater decrease in albuminuria with fenofibrate 
than with placebo was independent of baseline characteristics (except sex), while 
estimated GFR preservation was greater in patients with baseline dyslipidaemia and 
greater fenofibrate-related plasma triacylglycerol reduction. Therefore, different 
underlying mechanisms are likely. 
 
With regard to renal filtration function, our results imply two fenofibrate-specific 
effects: an initial, well-recognised plasma creatinine rise [16] and longer term 
estimated GFR preservation. The latter is most evident after treatment withdrawal. 
The early plasma creatinine change does not represent true nephrotoxicity, since there 
was rapid reversion to pre-treatment levels in those subsequently allocated placebo 
after the run-in phase. In addition, plasma creatinine after washout at 5 years in those 
allocated fenofibrate fell below that of the placebo-treated patients. The chronic 
underlying decline in renal function among fenofibrate-treated patients was 
nevertheless still about twice that associated with normal ageing in the absence of 
diabetes (1.9 versus 0.9 ml min
−1
 1.73 m
−2
 per year) [17]. The potential for reno-
protective (reduction/prevention of estimated GFR loss and/or albuminuria) 
treatments to cause acute reversible changes in plasma creatinine (e.g. due to altered 
haemodynamics) and then longer term beneficial changes in creatinine (e.g. structural 
preservation) was highlighted by Heerspink et al. [18-20]. These effects can be 
differentiated through a washout study, without which structural preservation may be 
missed [18]. Interestingly, fenofibrate use in a mouse model of type 2 diabetes was 
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linked with reduction in albuminuria, as well as histopathological improvements, e.g. 
reduced glomerular hypertrophy and reduced mesangial expansion [10]. The 
ACCORD Lipid trial, which examined patients on a background of statin treatment 
and high use of renin–angiotensin system blockade, recently confirmed our finding 
that fenofibrate caused an acute plasma creatinine rise and long-term reduction of 
micro- and macroalbuminuria, with no adverse effect on end-stage renal disease 
compared with placebo [1, 2]. A Helsinki sub-study examined renal function in 170 
Finnish participants in FIELD [21]. The investigators were unable to demonstrate a 
reduction in albuminuria with fenofibrate, despite the highly significant findings in 
the whole FIELD trial and the ACCORD trial, presumably due to the small sample 
size. They also found a greater fall in estimated GFR in patients allocated fenofibrate 
compared with placebo, in keeping with our on-study findings. However, the study 
had no washout phase and was therefore not able to unmask the underlying GFR 
preservation demonstrated now by us.  
The cystatin C elevation reported in the Helsinki sub-study may indicate altered 
glomerular function, but might also arise from other clinical and pharmacological 
factors [22, 23]. The reasons behind the initial plasma creatinine rise associated with 
fenofibrate have yet to be fully ascertained. The rise appears to be partly due to a 
decrease in creatinine clearance [16, 21] without reduced inulin-derived GFR [16, 24], 
raising the possibility of interference with the active secretion pathway for creatinine 
in the proximal tubule. In support of this possibility we observed significantly greater 
increases in plasma creatinine in response to fenofibrate in FIELD patients receiving 
cimetidine (a well recognised inhibitor of this tubular secretion) than those seen in 
others (p = 0.002). Based on our data, there is no evidence of permanent renal injury. 
Ansquer et al. hypothesised that reduced tubular secretion could have accounted for 
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the decrease in creatinine clearance they observed, although tubular function assessed 
by retinol binding protein levels was not changed significantly [16]. Hottelart et al. 
demonstrated increased creatinuria with no fall in creatinine clearance [25]. 
Fenofibrate effects on renal plasma flow in these two studies were also contrasting 
[16, 25], but both concluded there was no loss of glomerular function. While this is 
encouraging, further research is warranted. Hottelart et al. proposed that an 
endogenous source of creatinine, presumably from muscle, could augment serum 
creatinine during fenofibrate treatment [25]. In FIELD, plasma creatine 
phosphokinase rose 2.4% in those on fenofibrate vs 0.5% in those on placebo (p=0.06 
for difference) over 5 years of follow-up, while increases in plasma creatinine 
correlated weakly with increases in creatine phosphokinase (after 6 weeks run-in, 
r=0.09, p<0.001; at 5 years, r=0.14, p<0.001), suggesting fenofibrate-associated 
increased muscle turnover may have contributed in part to the creatininaemia. Thus 
various hypotheses on the cause of the acute and sustained creatinine elevation due to 
fenofibrate are possible: (1) increased muscle production of creatine; (2) changes in 
active tubular creatinine secretion; (3) reduced glomerular function; and (4) altered 
renal plasma flow. Some or all of these may apply. Regardless of the physiology 
underlying the increase in creatinine, it is definitely reversible and appears to be a 
separate process from the underlying renal preservation which is ‘masked’ during 
active treatment. 
 
The pattern of early plasma creatinine rise and subsequent attenuation of the rate of 
renal decline with fenofibrate therapy is similar to that seen with ACE inhibitors, 
albeit through different mechanisms. ACE inhibitors increase creatinine through a 
true reduction in GFR secondary to reduced intraglomerular pressure, but are reno-
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protective because they decrease glomerular hyperfiltration and have anti-fibrogenic 
effects [26, 27]. The underlying reno-protective mechanisms of fenofibrate remain to 
be fully elucidated (ESM Table 5). 
 
Hypertriacylglycerolaemia and the degree to which it is reduced were the only 
characteristics that predicted greater than average preservation of estimated GFR with 
fenofibrate. As statin trials have not consistently shown reno-protective effects, 
despite moderate triacylglycerol reduction [28-30], the benefits of fenofibrate may not 
be solely lipid-mediated. This may reflect antioxidant and anti-inflammatory effects 
[31]. Triacylglycerols have been linked to nephropathy through mesangial cell uptake 
of very low-density lipoprotein (VLDL), inducing foam cell formation [32] and 
through VLDL induction of plasminogen activating inhibitor-1 (PAI-1) with 
upregulated coagulation and intra-renal microthrombi [33]. HDL does not greatly 
alter PAI-1 release [34], but has been shown in animals and humans to be reno-
protective [35], perhaps through suppression of inflammatory cell adhesion molecules, 
anti-oxidant effects and reverse cholesterol transport [36, 37]. Peroxisome-
proliferator-alpha receptor agonists such as fenofibrate may have potential benefits 
through most of these mechanisms [31]. The observed relationships between both 
hypertriacylglycerolaemia and dyslipidaemia and renal function in the FIELD study 
may also reflect insulin resistance which is a risk factor for renal dysfunction [38].  
The arguably small absolute fall in estimated GFR in the placebo group (8% over 5 
years) may reflect good control of blood pressure, glycaemia and dyslipidaemia [39]. 
However, based on the placebo rate of estimated GFR loss over 5 years, fenofibrate’s 
estimated GFR benefit would be the equivalent of 3.6 kidney-years saved. This 
protection was observed across most subgroups and was irrespective of baseline or 
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on-study commencement of renin–angiotensin system blockers. As the subsequent 
initiation of renin–angiotensin system blockers was higher in the placebo arm (30.1% 
vs 25.3% in fenofibrate group, p<0.001), the reno-protection provided by fenobrate 
may have been underestimated. Similarly, commencement of other lipid medications, 
including statins, was greater in placebo-allocated patients (36.2% vs 19.3% in 
fenofibrate group) and did not influence benefit. Fenofibrate benefits were 
independent of blood pressure despite an associated lowering of systolic BP by 
approximately 2 mmHg.  
 
Three-quarters of FIELD placebo-treated patients were normoalbuminuric at baseline, 
with 2.8% developing micro- or macroalbuminuria each year, which is similar to 
progression rates in the UK Prospective Diabetes Study (2.5%) and Microalbuminuria, 
Cardiovascular, and Renal Outcomes–Heart Outcomes Prevention Evaluation 
(MICRO-HOPE) study (2.2%) [40, 41]. Improvement in urinary ACR with 
fenofibrate was twofold greater than with placebo. Implications for cardiovascular 
protection may be relatively small for normoalbuminuric patients, but are greater for 
those with macroalbuminuria (ESM Fig. 2) [9], in whom the 11 mg/mmol difference 
in mean ACR would represent a 1% lower absolute 5 year risk of cardiovascular 
disease, based on a diabetes-specific risk calculator [42]. 
 
Our study has limitations. The washout sub-study was relatively small, but 
nevertheless adequately powered for the outcomes examined and with highly 
statistically significant results obtained. A larger study might have revealed other 
subgroups likely to benefit more from fenofibrate.  Renal assessment through inulin 
and p-amino hippurate clearance is impractical in large trials and estimated GFR has 
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limitations [13]. Nevertheless, comparative temporal within-patient changes in 
estimated GFR and particularly plasma creatinine in our large sample are likely to 
remain robust [43]. Moreover, very few participants withdrew due to plasma 
creatinine rises and, to our knowledge, the washout study is the first of its type among 
agents with renal effects. Re-analysis of our data using an estimated GFR formula 
(EPI-CKD) with greater accuracy at higher estimated GFR levels [44] did not alter 
our conclusions (slightly smaller but still significant benefit [data not shown]). Serum 
cystatin C, an indicator of renal dysfunction in type 2 diabetes, also modestly 
increases in patients on fenofibrate without any change in inulin clearance [16] and 
reverts shortly after drug withdrawal (personal communication, J.-C Ansquer, 
Laboratoires Fournier SA, Dijon, France ), but has not yet been measured in FIELD. 
A very similar rise in serum cystatin C was also demonstrated in the Helsinki sub-
study [21], but measurements were not repeated after treatment withdrawal. 
Additional FIELD analyses will facilitate understanding of why fenofibrate may 
reversibly increase cystatin C [16]. Urinary ACR was measured in FIELD less often 
than plasma creatinine, but the fenofibrate-associated changes were nevertheless 
highly significant. Regression to the mean is unlikely to play a major role in these 
data, as there was no entry criterion related to albuminuria and baseline measures of 
albuminuria and estimated GFR were both derived as the mean of two pre-
randomisation values. One strength of the FIELD study is that it is one of the largest 
type 2 diabetes randomised trials examining pre-specified renal outcomes. We 
incorporated variables available in a usual-care context to ensure relevance to clinical 
practice. 
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In FIELD, there was evidence that fenofibrate had significant beneficial effects on 
laser treatment for diabetic retinopathy [4] and lower limb amputations, including in 
instances regarded as having a predominantly microvascular aetiology [5]. The 
protective effect of fenofibrate on these two microvascular complications of diabetes 
is consistent with the present findings of a slowing of the progression of diabetic 
microvascular renal disease. The number needed to treat with fenofibrate to prevent 
one patient progressing to micro- or macroalbuminuria is 54. This compares 
favourably with 66 to 100 for ACE inhibitor use in MICRO-HOPE [41]. In the 
FIELD study, the number needed to treat to prevent one patient worsening by at least 
one estimated GFR grouping (< 30, 30-<60, 60-<90 or ≥ 90 ml min−1 1.73 m−2) was 
25 and only 10 for dyslipidaemic patients. By comparison, the numbers needed to 
treat to prevent one cardiovascular event overall and in dyslipidaemic FIELD patients 
are 70 and 23 respectively; for ocular laser therapy overall and in patients with 
existent retinopathy, the number needed to treat is 90 and 17 respectively, and for 
amputation prevention overall and in those with prior foot ulcer and albuminuria, it is 
197 and 25 respectively. Because of greater cardiovascular therapy and statin uptake 
in the placebo group, these may be underestimates. 
 
In conclusion, we demonstrated in pre-specified analyses that fenofibrate reduces 
albuminuria progression and may reduce loss of renal function. This appears to be 
independent of, and therefore additive to renin–angiotensin system blockade and 
glycaemic control. We found no evidence that the initial plasma creatinine rise 
represented true renal injury, a finding that has important implications for clinical care. 
The size and consistency of the estimated GFR and albuminuria benefits support use 
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of fenofibrate in type 2 diabetes to reduce renal morbidity, especially in patients with 
dyslipidaemia. Confirmatory studies are merited. 
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FIGURE LEGEND 
 
Fig. 1 Trial profile of renal study. eGFR, estimated GFR 
 
Fig. 2 Changes among all 9,795 patients over 5 years follow-up in (a) plasma 
creatinine, (b) estimated GFR and (c) ACR in the fenofibrate (continuous lines and 
squares) and placebo (dashed lines and triangles) groups. Changes are shown from 
screening for plasma creatinine and urinary ACR, and from 4 months for estimated 
GFR. *Values for estimated GFR in patients while on fenofibrate may be unreliable 
 
Fig. 3 Changes among 661 participants in the washout sub-study from baseline to 8 
weeks after study close for (a) mean plasma creatinine in the fenofibrate group 
(continuous line) and placebo group (dashed line), and (b) for estimated GFR at 
baseline (white) and after washout (black). Values are mean (95% CI); 
†
p=0.0003; 
‡
p=0.065; 
§
p<0.0001 
 
Fig. 4 Forrest plot of the change in estimated GFR by treatment group (washout 
minus baseline, ml min–1 1.73 m–2) for baseline subgroups. aIndependently 
significant change from baseline (p<0.05); subgroups are based on prespecified 
classifications based on clinical relevance or approximate medians. 
b
Low HDL-
cholesterol: men <1.03 mmol/l, women <1.29 mmol/l. 
c
Treatment×subgroup 
interactions were significant only for triacylglycerol (p=0.03) and marked 
dyslipidaemia (p=0.03). 
d
Marked dyslipidaemia: triacylglycerol ≥2.3 mmol/l and low 
HDL-cholesterol. 
e
Microalbuminuria was defined as urinary ACR ≥2.5 mg/mmol 
(men) and ≥3.5 mg/mmol (women); macroalbuminuria as  urinary ACR >25 
mg/mmol (men) or >35 mg/mmol (women) (revised sex-specific cut-points) [45]. 
ARB, angiotensin-receptor blocker 
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Table 1 Baseline characteristics of all patients by treatment 
 
Characteristic 
Treatment 
Placebo Fenofibrate 
n 4900 4895 
General    
  Male, n (%) 3067 (62.6) 3071 (62.7) 
  Age at visit 1 (years) 62.23 (6.91) 62.23 (6.83) 
  Duration of diabetes (years) 5.00 (2.00–10.00) 5.00 (2.00–10.00) 
Clinical history   
  Nephropathy, n (%)a 135 (2.8) 144 (2.9) 
Laboratory data   
  LDL-cholesterol (mmol/l) 3.07 (0.66) 3.07 (0.64) 
  HDL-cholesterol (mmol/l) 1.10 (0.26) 1.10 (0.26) 
  Triacylglycerol (mmol/l) 1.73 (1.34–2.30) 1.74 (1.35–2.34) 
  Marked dyslipidaemia, n (%)
b
 970 (19.8) 1044 (21.3) 
  HbA1c (%) 6.85 (6.10–7.75) 6.85 (6.05–7.80) 
  Plasma creatinine (µmol/l) 77.40 (15.66) 77.73 (15.91) 
  Urine ACR (mg/mmol) 1.10 (0.60–2.90) 1.15 (0.60–3.00) 
  Normoalbuminuria, n (%) 3643 (74.5) 3617 (74.1) 
  Microalbuminuria, n (%) 1040 (21.3) 1064 (21.8) 
  Macroalbuminuria, n (%) 204 (4.2) 200 (4.1) 
  eGFR (ml min−1 1.73 m−2)  87.8 (18.3) 87.6 (18.5) 
  eGFR <60, n (%) 224 (4.6) 295 (6.0) 
  eGFR 60–<90, n (%) 2657 (54.2) 2561 (52.3) 
  eGFR ≥90, n (%) 2019 (41.2) 2039 (41.7) 
Medication   
  ACE inhibitor, n (%) 1725 (35) 1716 (35) 
  ARB, n (%) 265 (5) 280 (6) 
  Any insulin, n (%)
c
 672 (13.7) 674 (13.8) 
Values are mean (SD) or median (interquartile range), unless indicated otherwise  
aSelf-reported at baseline 
bMarked dyslipidaemia: low HDL-cholesterol (men <1.03 mmol/l, women <1.29 mmol/l) with high triacylglycerol 
(≥2.3 mmol/l) 
cAlone or in combination 
ARB, angiotensin-receptor blocker; eGFR, estimated GFR; 
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Table 2 Pre-specified end-stage renal events by treatment 
 
 
aCategories not mutually exclusive 
bPost-hoc composite renal endpoints for comparison with other studies 
cExcluding renal deaths 
dIncluding renal deaths 
 Placebo Fenofibrate Total 
Variable na (%) na (%) na (%) 
Participants 4900 100 4895 100 9795 100 
Event       
  Plasma creatinine >400 µmol/l 3 (0.1) 6 (0.1) 9 (0.1) 
  Renal replacement therapy 21 (0.4) 16 (0.3) 37 (0.4) 
  Renal transplant 0 (0.0) 0 (0.0) 0 (0.0) 
  Death from renal disease 4 (0.1) 1 (0.0) 5 (0.1) 
  Total patients with ESRD 26 (0.5) 21 (0.4) 47 (0.5) 
  Doubling of serum creatinine 90 (1.8) 148 (3.0) 238 (2.4) 
  Doubling of serum creatinine or ESRDb,c 103 (2.1) 152 (3.1) 255 (2.6) 
  Doubling of serum creatinine or ESRDb,d 105 (2.1) 152 (3.1) 257 (2.6) 
13900 patients screened 
9795 randomised 
4895 assigned fenofibrate 
3879 mortality status confirmed 
  630 urine ACR unavailable 
  581 eGFR unavailable 
4900 assigned placebo 
4885  mortality status confirmed 
  581  urine ACR unavailable 
  532 eGFR unavailable 
 1334 declined 
 2625 not eligible 
 146 other reasons 
 10 lost to follow-up 
 5 withdrew consent 
 12 lost to follow-up 
 4 withdrew consent 
 4885  returned for 8-week 
  washout 
 0 eGFR unavailable 
 326  returned for 8-week 
  washout 
 1 eGFR unavailable 
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